Xiuhong Peng
Overview
Explore the profile of Xiuhong Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang H, Yang T, Mu W, Peng X, Liu T, Weng L, et al.
Small
. 2025 Feb;
:e2411299.
PMID: 40018887
Herein, an engineered nanocomposite (FZS) was constructed containing zinc-based nanozyme(ZS), Hemin and Ca ions with further surface modification of phospholipid and folic acid (FA) for primary and metastatic breast cancer...
2.
Yang T, Zhang S, Nie K, Peng X, Huo J, Fu X, et al.
Biochem Pharmacol
. 2025 Feb;
233:116790.
PMID: 39894307
Although ferroptosis as an emerging way exhibits tremendous promising in the therapy of hepatocellular carcinoma (HCC), the novel therapeutic agents targeting ferroptosis are still scarce. In our previous study, we...
3.
Li R, Yang T, Peng X, Feng Q, Hou Y, Zhu J, et al.
Nanomicro Lett
. 2024 Jun;
16(1):226.
PMID: 38916749
The development of supramolecular hosts which can efficiently encapsulate photosensitizers to improve the photodynamic efficacy holds great promise for cancer therapy. Here, we report two perylene diimide-based metallacages that can...
4.
He X, Peng X, Zhang S, Yang T, Huo J, Zhang Y
Toxicon
. 2024 Jun;
246:107795.
PMID: 38849008
Amphotericin B (AmB) induced liver and kidney injury is often responsible for hepatic and renal dysfunction. Therefore, the protection strategy on liver and renal functions in patients treated with AmB...
5.
Liu F, Yang T, Chang X, Chen L, Cheng C, Peng X, et al.
Natl Sci Rev
. 2024 May;
11(5):nwae113.
PMID: 38698903
Precise and efficient therapy of malignant tumors is always a challenge. Herein, gold nanoclusters co-modified by aggregation-induced-emission (AIE) molecules, copper ion chelator (acylthiourea) and tumor-targeting agent (folic acid) were fabricated...
6.
Liu J, Yang T, Zhang H, Weng L, Peng X, Liu T, et al.
Bioact Mater
. 2024 Jan;
34:354-365.
PMID: 38269307
Tumor microenvironment (TME), as the "soil" of tumor growth and metastasis, exhibits significant differences from normal physiological conditions. However, how to manipulate the distinctions to achieve the accurate therapy of...
7.
Liu C, Yang T, Cheng C, Huo J, Peng X, Zhang Y
Phytother Res
. 2023 Oct;
38(1):131-146.
PMID: 37821355
Neuroblastoma and glioblastoma are primary malignant tumors of the nervous system, with frequent relapse and limited clinical therapeutic drugs. The failure of their treatment is due to the tumor cells...
8.
Zhou J, Chen Z, Li J, Deng Q, Peng X, Li L
Zhong Nan Da Xue Xue Bao Yi Xue Ban
. 2023 Jun;
48(4):538-549.
PMID: 37385616
Objectives: Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases in women with reproductive age, which is associated with hyperandrogenism, insulin resistance, and ovulatory dysfunction. Progesterone receptor...
9.
Zhang X, Miao H, Zhou J, Chen Y, Ou Y, Song Y, et al.
Front Endocrinol (Lausanne)
. 2023 Feb;
14:1109861.
PMID: 36793270
Background: Polycystic ovary syndrome (PCOS) not only increases fertility challenges for women of reproductive age, but also leads to increased complications during pregnancy and even affects the birth weight of...
10.
Zhong M, Tu Y, Peng X, Song Y, Zhou J, Zhang X, et al.
Gynecol Endocrinol
. 2023 Jan;
38(12):1153-1157.
PMID: 36634704
Background: Polycystic ovarian syndrome (PCOS) affects up to 18% of reproductive-aged women and raises the risk of venous thromboembolic disease (VTE), due to metabolic features and an apparent fibrinolytic state....